Track SCYNEXIS, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

SCYNEXIS, Inc. SCYX · Stock Open SCYNEXIS, Inc. in new tab

3.21 USD
EPS
-0.23
P/B
0.39
ROE
-18.38
Beta
1.22
Target Price
32.67 USD
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
EPS-0.23
Book Value9.07
Price to Book0.39
Debt/Equity2.91
% Insiders2.053%
Growth
Revenue Growth-0.83%
Estimates
Forward P/E-2.12
Forward EPS-1.65
Target Mean Price32.67

DCF valuation

Model fair value for SCYNEXIS, Inc. (SCYX)
Result
Sign in to run the valuation for SCYX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus None · mean target 32.67 USD (low 32.00, high 33.00) · as of 10 Nov 2026
Low 32.00
Mean 32.67
High 33.00
Price 3.21
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

SCYNEXIS, Inc. Logo SCYNEXIS, Inc. Analysis (SCYX)

United States Health Care Official Website Stock

Is SCYNEXIS, Inc. a good investment? SCYNEXIS, Inc. (SCYX) is currently trading at 3.21 USD. Market analysts have a consensus price target of 32.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: SCYNEXIS, Inc. is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -1.65.

Investor FAQ

Does SCYNEXIS, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is SCYNEXIS, Inc.?

SCYNEXIS, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -0.23.

Company Profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Exchange Ticker
NMS (United States) SCYX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 17, 2020 1:10
June 1, 2026 0.12
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion